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ABSTRACT 
Yermakoff, Jeannee Karen. Ph.D., University of Rhode Island, 1980. 
Characterization of the Fibrotic Lesion in Dibutyltin-induced Experi-
mental Liver Injury. Major Professor: Dr. George C. Fuller. 
Administration of di-n-butyltin dichloride (DBT) by oral intubation 
has been shown to produce hepatic fibrosis in rats. Unlike post-necro-
tic experimental fibrosis, DBT-induced hepatic fibrosis progresses from 
inflanunation and biliary injury. The relationship of histological 
changes to various parameters of collagen synthesis and liver injury 
were investigated. In vitro collagen synthesis was determined by incu-
bation of liver biopsies with labelled praline and subsequent digestion 
with protease-free collagenase. Prolyl hydroxylase activity in liver 
homogenates was taken as a second parameter reflecting the rate of 
collagen synthesis. DBT administration (20 mg/kg/day, p.o.) produced 
a progressive increase in both in vitro collagen synthesis and prolyl 
hydroxylase activity from 0 to 4 days. The increases in these two para-
meters were significantly correlated and both accompanied the appearance 
of inflammatory cells in portal tracts and bile duct proliferation. 
Serum alanine transaminase activity was increased after 4 days of DBT 
administration. DBT administration (20 mg/kg, q.o.d., p.o.) for 12 days 
produced increased prolyl hydroxylase activity, an increase in the per-
cent of in vitro collagen synthesis, and the accumulation of hydroxy-
praline in the liver. These biochemical changes were associated with 
fibrosis, bile duct proliferation and extensive inflammation in the 
portal tracts. Alanine transaminase and alkaline phosphatase activities 
in serum were unchanged after 12 days of DBT treatment. Rats 4 weeks 
of age at the start of treatment were relatively resistant to the 
effects of DBT (20 mg/kg, q.o.d., p.o.) administered for 12 days. 
Prolyl hydroxylase activity in these 4-week old rats was 125% of control 
compared to 150% and 215% in the 9- and 14-week old groups, respectively. 
Leucocytosis and weight loss usually associated with DBT-induced liver 
injury were absent in these younger rats and histology was similar to 
that of control animals. Thymus atrophy was observed in the 4-week old 
rats. Investigation of lymphocyte-mediated cytotoxicity, delayed type 
hypersensitivity, and immunofluorescence in rats 9 weeks of age at the 
start of treatment failed to reveal an immunologic reaction against DBT 
or liver. The relationship of differences in hepatic microsomal meta-
bolism to the age-related phenomena was investigated using an inhibitor 
of microsomal enzymes, SKF 525A. Administration of SKF 525A (50 mg/kg, 
b.i.d., p.o.) concomitantly with DBT (20 mg/kg/day, p.o.) resulted in 
an interaction between these two compounds with respect to their effect 
on prolyl hydroxylase activity. The elevation in serum alanine trans-
aminase activity seen with DBT treatment alone after 4 days was com-
pletely prevented by the simultaneous administration of SKF 525A. 
Periportal inflammation and biliary chan?es were absent in rats recei-
ving DBT and SKF 525A. 
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INTRODUCTION 
The toxicity of organotin compounds became apparent in the mid 
1950s following their unfounded use as therapeutic agents and ensuing 
disastrous results. The toxicology of organotin derivatives remains of 
interest today as a result of their continued industrial uses. Alkyl-
tins are widely used as stabilizers and catalysts by the plastics indus-
tries (~iver, 1973) and as biocidal agents (McCollister and Schober, 
1975). 
The hepatic and biliary manifestations of dialkyltin toxicity in 
rats has been known for some time (Barnes and McGee, 1958; Barnes and 
Stoner, 1958; Gaunt et al., 1968) ~ More recently, toxicity to thymus-
dependent lymphocytes in vitro and impairment of cell-mediated immune 
functions in rats have been attributed to the dialkyltins (Seinen et 
al., 1977a and 1977b). 
Administration of di-n-butyltin dichloride (DBT) to rats has been 
shown to produce an experimental model of hepatic fibrosis which is 
associated with periportal inflammation and bile duct proliferation 
(Yermakoff, 1978). This investigation attempts to further characterize 
the fibrotic hepatic lesion induced by this organotin compound. The 
relationship of DBT-induced changes in biochemical parameters of hepa-
tic collagen synthesis and liver injury to the associated histopathol-
ogy is examined with special emphasis on hepatic inflannnation. 
1 
A possible connection between this compound's hepatotoxic and immuno-
toxic properties is investigated. The role of metabolism in DBT-
induced liver injury is also examined. 
2 
LITERATURE SURVEY 
Collagen Biosynthesis 
Collagen is the most ubiquitous protein in higher vertebrates. 
Its pr~sence in the extracellular matrix, as rigid fibers consisting of 
cross-linked collagen molecules, provides structural support in these 
organisms. Collagen molecules each consist of three alpha (a) chains, 
left-handed helices, coiled into a unique right-handed triple helix. 
At least five, and possibly more, types of collagen molecules have 
been identified; these have been recently reviewed by Eyre (1980). 
Intersitial collagens include types I and III. Type ·I, found primarily 
in skin, bone, and tendon, consists of two al chains and one a2 chain, 
which are distinguishable by their separation on carboxymethylcellulose 
colunms. It is represented by the molecular formula [al{I)] 2az. Types 
II and III each consist of three identical al chains, with each type 
differing slightly in amino acid composition. Type II ([al(II)] 3) is 
found in cartilage and type III {[al(III)] 3) in fetal tissue, uterus 
and blood vessels. Collagen of the basal lamina, basement membrane 
collagen, is distinct from the previous three in its lack of fibrillar 
structure. Its precise molecular structure, originally thought to be 
[al(IV)] 3 , is under question. Recently, collage~ aA and aB chains have 
been isolated . from various sources including human placenta, infant 
cartilage (Rhodes and Miller, 1978), and lung parenchyma (Madri and 
Furthmayr, 1979). Their molecular formula(s) is uncertain. 
3 
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Collagen is unique among proteins in the extent of its post-trans-
lational modifications. Its biosynthesis consists of the assembly of a 
proline-, lysine-, and glycine-rich polypeptide precursor, procollagen. 
Hydroxylation of both proline (Prockop and Juva, 1965) and lysine 
(Sinex et al., 1959) has been shown to occur subsequent to the incor-
poration of these amino acids into procollagen chains. Intracellular 
hydroxylation of collagen precursor has been shown to be requisite for 
stable helix formation and secretion (Uitto and Prockop, 1974). Follow-
ing hydroxylation of lysine, some of these residues are glycosylated to 
galactosylhydroxylysine and glucosylgalactosylhydroxylysine (Spiro and 
Spiro, 197la and 197lb). Cellular processing of procollagen a chains 
also includes interchain disulfide-bond linkage in nonhelical regions 
of the molecule which is essential for triple-helix formation 
(Speakman, 1971). 
Following the secretion of procollagen, terminal nonhelical 
regions are enzymatically removed (Tuderman et al., 1978; Davidson et 
al., 1977). Collagen cross linking occurs through additional extra-
cellular processing by the enzyme lysyl oxidase, which oxidatively dea-
minates specific lysine residues leaving aldehyde moieties. These, in 
turn, form cross links through condensation reactions (Siegal et al., 
1970). 
In mammals, collagen is cleaved by collagenases to form two frag-
ments, referred to as TCA and TCB, which are then degraded further by 
relatively nonspecific proteases (Perez-Tamayo, 1978). The enzyme pro-
bably exists in vivo in three forms: latent enzyme, free enzyme, and 
enzyme bound to collagen. 
Inflannnatory and Immunologic Processes 
in Hepatic Fibrosis 
It is well-established that the amount of collagen is increased 
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in liver disease resulting from exposure to various xenobiotics. Such 
fibrosis is associated with chronic alcoholism (Chen and Leevy, 1975; 
Mann et al., 1979), exposure to environmental toxicants (Popper et al., 
1979), and certain therapeutic agents (Maddrey and Boitnott, 1979). 
Xenobiotic-induced liver disease has been broadly classified into three 
categories: cytotoxic, which include steatosis; cholestatic; and mixed 
cytotoxic and cholestatic (Zinnnerman, 1978). 
Regardless of etiology and histologic classification, all types of 
chemical-induced hepatic injury share the possibility of progression to 
fibrosis via one or a combination of the following processes. The first 
of these is the stimulation of collagen production by or increased pro-
liferation of collagen-producing cells. The second is the increased 
extracellular maturation of collagen fibrils from secreted procollagen. 
A decrease in collagenolytic processes may result in fibrosis. 
Finally, a minor contribution to fibrosis may result from the collapse 
and aggregation of preformed collagen fibers. 
The mechanism of chemical-induced hepatic fibrogenesis has been 
extensively investigated utilizing models of fibrosis induced by com-
pounds such as carbon tetrachloride (Aterman, 1954; McLeon et al., 
1969; McGee et al., 1973) and dimethylnitrosamine (Madden et al., 1970), 
which are predominately post-necrotic. These studies have led to the 
hypothesis that hepatocytes, upon their death, release products to 
6 
stimulate fibrogenesis (Popper, 1975). However feasible, the applica-
tion of this hypothesis -to most types of xenobiotic-induced liver fibre-
sis in humans is somewhat untenable. Specifically, alcoholic and drug-
induced fibrosis in humans is connnonly associated with an imflannnatory 
and/or innnunologic component not seen in these post-necrotic models of 
hepatic fibrosis. 
Inflannnatory and/or innnunologic processesa have been associated 
with a broad range of fibrotic diseases. Fibrogenesis in inflammatory/ 
innnunologic disease states has been attributed to fibroblast prolifer-
ation (Wahl et al., 1978), increased collagen synthesis by fibroblasts 
(Johnson and Ziff, 1976), and fibroblast chemotaxis (Posthelwaite et 
al., 1976) in response to factors derived from innnunocompetent cells. 
Recently, evidence has been accumulating that immunocompetent 
cells and products released by these cells play a substantial role in 
the initiation and/or perpetuation of hepatic fibrogenesis. In both 
hepatitis B (HB) antigen-negative and HB antigen-positive hepatitis, 
autoimmune aggression has been implicated as a means of perpetuating 
liver cell injury (Paronetto and Popper, 1976). In a recent review, 
Buschenfelde et al. (1979) suggested that the HB virus by itself is not 
injurious to cells and that the host innnune response is responsible for 
the tissue damage in acute and chronic HB virus-induced hepatitis. In 
HB antigen-negative hepatitis, antibody against native liver membrane 
antigens has been detected, which corresponds with histologic evidence 
~nless otherwise specified, throughout this text these processes 
are considered together since it is often difficult to clearly distin-
guish one from the other. Inflannnation may be a component and/or con-
sequence of an immune response (Voisen, 1977). 
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of inflammation and continuing necrosis (Hopf et al., 1976). A cell-
mediated immune response to collagen has been suggested to initiate the 
progression of hepatitis to cirrhosis (Chen et al., 1978). In primary 
biliary cirrhosis as many as one-third of patients have been estimated 
to possess antiductular cell antibodies and 80% antimitochondrial anti-
bodies (Schaffner, 1979). Finally, experimental liver injury has been 
produced in rats by immunization with heterologous sera lParanetto and 
Popper, 1966). 
Inflammatory and/or immunologic processes are part ot the patho-
genetic scenario of drug- and chemical-induced hepatic fibrosis in many 
instances. However, it is difficult to determine the relative contri-
bution of these processes to the etiology and perpetuation of such 
liver disease. The primary reaction may be an inflammatory and/or 
immunologic response to the drug and/or drug products, a toxic reaction 
to the compound and/or its metabolites, or any combination of these 
phenomena (Maddrey and Boitnott, 1979). 
Understanding of immunologic reactivity to drugs and other chemi-
cals, or drug allergy, has been advanced by recent work with penicilla-
mine. This drug has been shown to react with compounds containing 
disulfide groups to form disulfides which are at least partially res-
ponsible for the immune response resulting from penicillamine adminis-
tration (Dewdney, 1979). Such work has suggested that the potential 
for drug allergy is a function of a compound's ability to form covalent 
bonds with macromolecules at physiological conditions (McGovern et al., 
1970; Dewdney, 1979). The knowledge of the formation of haptenic 
determinants has been of some predictive value in drug allergy, but 
8 
unequivocal demonstration of cause and effect has been hampered by the 
diversity of immunologic responses and methodological inadequacies 
(DeWeck, 1979). 
The association of drug with disease in suspected hepatic mani-
festations of drug allergy has been even more elusive. When immune 
reactivity to a drug can be demonstrated, it does not necessarily imply 
that such reactivity is the cause of liver injury. Consequently, the 
nature of immunologic reactions involved in hepatic drug allergy have 
not been clearly identified (Girard, 1974). 
Hepatic manifestations of drug and chemical allergy are commonly 
diagnosed by indirect means such as recurrence of symptoms with repeated 
exposure. The major problem resulting from this practice is the identi-
fication of host idiosyncracy as drug allergy. Nonetheless, much of the 
evidence has been convincing. Halothane produces jaundice in a small 
number of patients (Zimmerman, 1972), and, in a remarkably thorough 
case study, repeated episodes of hepatitis have been correlated with 
exposure to halothane in an anesthetist (Klatskin and Kimberg, 1969). 
Primary biliary cirrhosis, a disease in which the majority of patients 
demonstrate autoantibodies, is often associated with a history of drug 
allergy (Paronetto et al., 1964a); phenothiazines and androgenic ster-
oids produce liver injury similar to that seen in primary biliary cir-
rhosis (Dickson~ al., 1979). The environmental toxicant, 2,3,7,8-
' tetrachlorodibenzo-p-dioxin (TCDD), produces liver injury (Neal et 
al., 1979) and is suspected to be immunogenic (Luster et al., 1979) in 
mice. However, a connection between chemical-induced experimental liver 
injury and antigenicity of such toxicants has not been established. 
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Drugs and other chemicals may also produce a destructive cholangi-
tis in which inflammatory processes occur in the liver in the absence 
of evidence of immunologic phenomena (Zimmerman, 1978). Such inflamma-
tion has been suggested to be a reaction to cholestasis (Popper and 
Schaffner, 1970) although cholestasis is not always the primary event 
(Krstulovic, 1968). The distinction between such inflammatory reactions 
and immunologic processes is not well defined. In fact, it has been 
suggested that, in many cases, cholangitis is responsible for subsequent 
immunologic reactions (Popper and Schaffner, 1970). 
Developmental Aspects of Hepatic Drug Metabolism 
Clinical problems associated with pharmakokinetic differences bet-
ween the perinatal period and postnatal development through adulthood 
have become increasingly apparent in recent years. As always, there 
are exceptions. Yet, it is common for plasma half lives to be up to a 
magnitude greater in the neonate, apparent volumes of distribution to 
be substantially increased, and various drug metabolism processes to be 
sluggish compared to adulthood (Done et al., 1977). Unless dosage is 
adjusted accordingly, substantial toxicity is likely to occur in child-
ren as a result of extraordinarily high plasma drug levels. 
Investigation of developmental aspects of pharmacokinetic para-
meters in animals has largely been supportive of human data. Although 
changes in drug disposi~ion and excretion probably contribute (Niems 
et al., 1976), pharmakokinetic differences during development are 
largely a result of differences in drug metabolism. Striking variations 
occur during rat development in both biosynthetic reactions such as 
glucuronidation (Dutton, 1978) and oxidative reactions of the cyto-
chrome P450 monooxygenase system (Niems et al., 1976). This review 
will concern itself with the latter. 
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Although the pattern of variations in monooxygenase activity in 
the liver varies with substrate, sex, and species, certain generali-
zations can be made. Activity of microsomal enzymes usually begins to 
increase at birth, after which it either continues to rise, reaching 
a plateau at maturity, or peaks, returning to a plateau with maturation 
(Kato and Takanaka, 1968; Niems ~al., 1976). Although the metabolism 
of a few drug substrates, such as the hydroxylation of aniline in the 
rat, peaks as early as two weeks postnatal (Gram~ al., 1969), others, 
such as the N-demethylation of aminopyrine in the rat, peak as late as 
nine weeks (Henderson, 1971). Somewhere during three to eight weeks 
postnatal, adult levels of P450 monooxygenase capability is reached for 
most substrates (Gilette and Stripp, 1975). 
Various mechanisms have been proposed for decreased oxidative 
drug metabolism in young animals. Livers removed from rats injected 
with somatotropin demonstrated impaired in vitro microsomal metabolism 
of various drug substrates (Wilson, 1969) . Since levels of growth 
hormone decrease postnatally, somatotropin may play a permissive role 
in the developmental variations in drug metabolism. Pelkonen (1973) 
suggests that "endogenous ligands" in fetal liver contribute to 
decreased drug oxidations following the observation that binding 
spectra of aminopyrine in fetal liver are the inverse of the character-
istic type I spectra. 
11 
Biliary Excretion 
Biliary excretion has been shown to be a major route for the 
elimination of xenobiotics from the body in both animals and humans 
(Stowe and Plaa, 1968). Bile production arises from the active secre-
tion of bile salts by hepatocytes, which is accompanied by the secretion 
of water and electrolytes (Levine, 1978). Three apparently distinct 
transport processes have been recognized for the excretion in the bile 
of cationic, amnionic, and polar, but uncharged, molecules all with a 
minimum molecular weight somewhere between 200-300 (Levine, 1978). 
Subsequent to biliary excretion, xenobiotics may be excreted in the 
feces or, those with appropriate chemical properties, may be reabsorbed 
to enter the enterohepatic circulation. Compounds which enter this 
circulation tend to have prolonged half lives which may contribute to 
toxicity. In addition, this circulation has been shown to be prerequi-
site for the development of certain toxic reactions. Thompson et al. 
(1954) found that chloramphenicol, subsequent to hepatic metabolism 
and biliary excretion, is converted to a toxic metabolite in the gut 
and reabsorbed as such to produce thyroid hypertrophy and resultant 
metabolic disturbances. 
Substantial species variation has been observed in the biliary 
excretion of some compounds. Russell and Klaassen (1972) have shown 
that the bile/plasma concentration gradient of ouabain following 
administration to rats, rabbits, and dogs was four orders of magnitude 
greater in the rat than the latter two species. Observed differences 
in the monkey and rabbit in the biliary excretion of disodium chromo-
12 
glycate, a drug not subject to hepatic metabolism, suggests that species 
variation of xenobiotic excretion in the bile in not necessarily due to 
interspecies metabolic differences (Ashton et al., 1973). 
Hepatic metabolism plays a role in the biliary excretion of many 
xenobiotics. The contribution is most pronounced when compounds are 
increased in molecular weight and/or acquire a polar group through 
metabolism without which biliary excretion would not occur. This has 
been demonstrated in rats with compounds such as biphenyl (Millburn 
et al., 1967) and orphenadrine (Hespe and Kafoe, 1970). In both cases, 
the parent compound is not excreted in the bile unchanged although its 
hydroxylated and glucuronidated metabolites are excreted extensively. 
Decreased or absent bile flow occurs in cholestasis. The condition 
presents itself morphologically as bile plugs (Popper and Schaffner, 
1970) and biochemically as an elevation of serum alkaline phosphatase 
due to induction of this enzyme (Kaplan and Righetti, 1970). Chole-
stasis may be either extra- or intrahepatic, the former being associated 
with an obstruction such as a tumor or inflammatory lesion outside the 
liver. In either case, a cormnon disturbance of the secretion of bile 
salts and lipid micelles is thought to exist (Popper and Schaffner, 
1970). 
Organotin Toxicity 
Extensive investigation of the toxicity of organotin derivatives 
began in the mid 1950s. The impetus for this was the "Stalinon" 
disaster in France in 1954. The available information regarding the 
incident is reviewed by Barnes and Stoner (1959). "Stalinon" was the 
propriety name for a drug sold for the treatment of skin infections. 
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It was said to contain 15 mg/capsule of diethyltin diiodide. According 
to the recommended dosage, patients should have received approximately 
90 mg/day of this organotin; in reality, they ingested approximately 
80 mg/day of diethyltin and 10 mg/day of the contaminant triethyltin. 
Patients exhibited symptoms of both central nervous system and gastro-
intestinal toxicity, which resulted in approximately 100 deaths. 
In the 25 years since "Stalinon", investigations of organotins 
have revealed that both diversified and relatively potent toxicity 
results from these compounds; reviews are available on the subject 
(Barnes and Magos, 1968; McCollister and Schober, 1975; Kimbrough, 
1976). 
Organotin derivatives have been adopted for a variety of industrial 
uses in recent years. They have been used as stabilizers in the produc-
tion of polyvinyl chloride; catalysts in the making of polyurethane 
(Piver, 1973); and as miticides, fungicides, and anthelmintics 
(McCollister and Schober, 1975; ·Hunter, 1976). Since many of these 
biocides ultimately may contaminate food products, acceptable daily 
intakes have been established for organotin pesticides by the FAO/WHO 
Joint Expert Committees on Pesticide Residues (McCollister and Schober, 
1976). The values established range from 0.5 to 7.5 µg/kg/day, quite 
a constrast to the accepted use of organotin compounds a little more 
than two decades ago. 
The trialkyltins produce central nervous system toxicity, which 
has been attributed to reversible interstitial edema of the white 
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matter of the brain (Magee~ al., 1957). Inhibition of oxidative phos-
phorylation (Aldridge and Street, 1964) and swelling of liver mitochon-
dria (Wulf and Byington, 1975) have been observed in vitro in rat liver 
mitochondria with trialkyltin derivatives. Inhibition of muscular con-
tractility in vitro, associated with disruption of mitochondria, dis-
organization of muscle fibers, and depletion of neuromicrotubules, has 
also been observed (Tan and Ng, 1977). Tributyltin undergoes oxidative 
metabolism by the rat liver microsomal system (Kimmel et al., 1977) to 
form metabolites which retain much of the biologic activity of the 
parent compound (Aldridge and Street, 1977) or unstable metabolites 
which are rapidly destannylated. 
Dialkyltin compounds differ from their trialkyl counterparts in 
that the primary lesion of the former is biliary and hepatic injury 
(Barnes and Stoner, 1958; Barnes and Magee, 1958; Gaunt et al., 1968). 
Dibutyltin is the most active in this respect. Barnes and Magee (1958) 
reported bile duct injury and hepatic inflammation two days after oral 
administration of dibutyltin dichloride (50 mg/kg). After six months, 
hepatic fibrosis was evident. 
In addition to its effects on the liver, Middleton and Platt 
(1977) report an inflammatory reaction in rat skin following the appli-
cation of dibutyltin. Contact dermatitis from elastic fabrics with a 
vinyl chloride polymer component has been attributed to the presence of 
a dibutyltin stabilizer (Fisher, 1973). 
Seinen et al (1977a) have reported atrophy of the thymus, spleen, 
and popliteal lymph node in weaning rats and toxicity to rat thymocytes 
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in vitro from dibutyltin. Thymocyte-dependent immunity in rats was 
found to be impaired by dibutyltin administration (Seinen et al., 1977b). 
Allograft rejection was delayed, and the response toward t-depdendent 
antigen, but not t-independent antigen, was decreased. These effects 
were greater in rats treated pre- and postnatally. 
Dialkytin's toxic effects have been attributed to their ability to 
inhibit a-keto acid oxidases in liver mitochondria and brain brei of the 
rat (Aldridge and Cremer, 1955); inhibition of oxidative phosphorylation 
by binding to the adenosine-triphosphatase complex as seen in ox heart 
mitochondria (Cain et al., 1977); and impairment of amino acid transport 
by binding to membrane sulfydral groups in rat thymocytes (Miller et 
al., 1978). 
Kimmel et al. (1977) have shown that dibutyltin derivatives undergo 
hepatic microsomal monooxygenase metabolism in rats, at least in part. 
Metabolism was investigated by Kimmel et al. in rat liver microsomal 
system and in vivo in mice using 14c-dibutyltin diacetate. Unidentified 
dialkyl polar metabolites of dibutyltin were suggested to be butyl-
hydroxylated derivatives. The lesser amount of monoalkyltin recovered 
was thought to result from both nonenzymatic destannylation and decom-
position of unstable hydroxylated dibutyltin derivatives. The majority 
of labelled dibutyltin administered to mice was recovered in the feces 
between 42-90 hours suggesting biliary excretion. Other investigators 
have reported the concentration of dibutyltin in the bile to be slight-
ly higher than plasma levels 18 hours after oral administration in 
rats (Barnes and Magee, 1958). 
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Naproxen 
Naproxen (6-methoxy-a-methyl-2-napthaleneacetic acid) was synthe-
sized by Harrison et al. (1970) in an attempt to provide an improved 
antirheumatic drug, an effort which has proven to be successful 
(Muirden, 1978). Naproxen is reported to be more than ten times as 
potent as aspirin in preventing carrageenin-induced rat paw edema, a 
commonly used test for antiinflammatory activity (Roszkowski et al., 
1971). Its usefulness is also a function of its relatively long half 
life in animals and humans (Runkel et al., 1972) as compared to other 
nonsteroidal antiinflammatory drugs. 
Roszkowski et al. (1971) suggest that naproxen acts directly at 
the site of inflammation. Although some nonsteroidal antiinflannnatory 
drugs have been reported to produce their pharmacological effects at 
least partially by glucocorticoid agonist activity, naproxen does not 
appear to possess such properties (Feldman, 1978). Naproxen's effects 
in vivo are more likely to be related to its inhibition of prostoglan-
din synthesis . (Mcintyre ~ al., 1978). 
SKF 525A 
SKF 525A (8-diet~ylaminoethyl-diphenyl-n-propylacetate) has been 
shown to inhibit hepatic microsomal metabolism in vivo (Stitzel et al., 
1966), in vitro (Anders and Mannering, 1966a), and in an extracorporeal 
system (Stitzel~ al., 1968). Anders and Mannering (1966a) suggest 
that SKF 525A produces its effects by competitve inhibition with drug 
substrates. However, other investigators have found both noncompetitive 
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and competitive inhibition of the same drug substrate using SKF 525A 
before and after recrystallization with benzene (Jenner and Netter, 
1972). No explanation was offered for the effect of recrystallization; 
the structure of SKF 525A was unchanged. 
SKF 525A is not as meticulous in its inhibition of hepatic micro-
somal metabolism as originally suspected. It inhibits primarily oxi-
dative reaction in liver microsomes, but inhibition of some glucoroni-
dations has been reported (Levine et al., 1970). Its inhibitory effects 
do not extend to the metabolism of all drug substrates (Goldstein et 
al., 1974). In addition, its inhibition of drug metabolism appears to 
exhibit temporal dependence (Anders and Mannering, 1966b). Rats 
treated with SKF 525A for five days (50 mg/kg/day, i.p.) showed in-
creased hexobarbital metabolism 24 hours after the last dose of inhibi-
tor, and effect which was attributed to induction of microsomal enzymes. 
However, when these rats were given a sixth dose of SKF 525A, they 
exhibited significant inhibition of hexobarbital metabolism 135 minutes 
later. Based on these results, these investigators suggest that SKF 
525A maintains its inhibitory properties with both control and SKF 525A-
induced microsomal enzymes. 
SKF 525A has pharmacological effects in addition to those it exerts 
on drug metabolism. Infusion of this inhibitor into the renal artery of 
dogs at concentrations of 4 mg/minute and 8 mg/minute increased urine 
volum~ and sodium excretion, respectively (Marshall and Williamson, 
1964). Magus and Fouts (1967) reported that SKF 525A has variable 
effects on tryptophan pyrrolase including induction and "deattenuation" 
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of hydrocortisone induction of this enzyme in rat liver. This inhibitor 
has also been reported to impair gastrointestinal absorption of drugs in 
rats (McLean and Marchand, 1970). 
Biliary excretion of stilbestrol, phenolphthalein (Levine et al., 
1970), and 3-methylcholanthrene lLevine, 1972) was decreased in rats as 
a result of SKF 525A administration. This effect was thought to occur 
as a result of SKF 525A's effect on metabolism of these drugs since 
this inhibitor had no effect on the biliary excretion of administered 
phenolphthalein glucuronide (Levine et al., 1970). Hespe and Kafoe 
(1970) investigated the possibility that SKF 525A, or a metabolite, 
produced its effects on biliary excretion by competition for elimina-
tion in the bile. Following the finding that SKF 525A enhances biliary 
excretion of labelled orphenadrine, they testad the effects of pre-
treatment with unlabelled orphenadrine and found that excretion of the 
labelled compound was unchanged. This suggests that SKF 525A does not 
enhance elimination of compounds in the bile by competition with a 
saturable transport process. 
EXPERIMENTAL 
Materials 
Di-n-butylin dichloride was purchased from Aldrich Chemical 
Company (Milwaukee, WI). Naproxen (NAPROSYN) was a product of Syntex 
Laboratories (Palo Alto, CA). SKF 525A was provided by Smith, Kline, 
and French Laboratories (Philadelphia, PA). 
The following radioactive materials were purchased from New 
England Nuclear (Boston, MA): 2,3-3H-proline (specific activity 20 Ci/ 
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mmole), 4- H-proline (specific activity 25-30 Ci/mole) and Cr-sodium 
chromate (specific activity 200-500 Ci/g). 
Reagents purchased from Sigma Chemical Company (St. Louis, MO) 
included 2,3-dimercaptopropanol, 2-amino-2-methyl-l-propanol, p-nitro-
phenol, and p-nitrophenylphosphate. Dulbeccos Modified Eagles Medium 
(DME), RPMI 1640, and phytohemagglutinin were products of Grand Island 
Biologicals (Grand Island, NY). Concanavalin A was a product of 
Calbiochem (La Jolla, CA). FITC-conjugated anti-rat immunoglobulinG 
(IgG) was purchased from Miles Yeda, Ltd. (Rehovat, Israel). Eastman 
Kodak (Rochester, NY) was the supplier of 2,4-dinitrophenyl hydrazine. 
All reagents used throughout the investigation were analytical grade. 
Animals 
Male CD-Crl:CD(SD)Br rats were purchased from Charles River 
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Breeding Laboratories (Wilmington, MA). The rats were housed in groups 
of four to .six in colony cages at an ambient temperature ranging from 
24-27°C with alternating 12-hour light/dark cycles. Rats were fed 
Charles River Rat-Mouse-Hamster Formula and water ad libitum. 
Rats were 9 weeks of age at the start of treatment in all studies 
unless specified otherwise. 
Dibutyltin-induced Hepatic Fibrosis 
Fibrosis and associated liver injury were produced in rats by the 
oral administration of di-n-butyltin dichloride (DBT) in corn oil at a 
dose of 20 mg/kg. Unless otherwise specified, 0 to 4 day DBT adminis-
tration was on a daily basis and 12-day treatment on alternate days. 
Between 20-24 hours after the last administration of DBT, rats were 
killed by decapitation or, where serum assays were performed, by 
ether anesthesia and subsequent exsanguination. Livers, and sometimes 
thymuses and spleens, were removed and quickly chilled. Sections of 
liver tissue, and on occasion feet, were fixed and prepared for light 
microscopy with hematoxylin-eosin and trichrome stains. Liver samples 
were also prepared for determination of prolyl hydroxylase activity and 
in vitro collagen synthesis. Blood was added to vials containing 8.2 
mg disodium EDTA in 0.1 ml water for leucocyte counts or kept on ice for 
approximately 30 minutes and centrifuged at 3000 rpm to obtain serum. 
Additional Animal Treatments 
Naproxen was administered at a dose of 15 mg/kg every 12 hours by 
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oral intubation for 12 days. It was prepared as a 7.5 mg/ml suspension 
in corn oil. Controls received equivalent amounts of vehicle. 
SKF 525A was injected intraperitoneally at a dose of 50 mg/kg in 
saline every 12 hours for 4 days. Controls received equivalent amounts 
of saline. 
All drugs, regardless of the route of administration, were given 
in a volume of less than 1 ml. 
Preparation of Substrate for Prolyl Hydroxylase Assay 
The tritium labelled substrate was prepared by the method of 
Hutton et al. (1966) with some modifications. Twenty-five to 30 dozen, 
7-day old decapitated chick embryos were placed in ice-cold Krebs-
Ringer buffera (Stone and Meister, 1962). After washing twice with 
ice-cold Krebs, embryos were minced in the presence of a small amount 
of ice-cold Krebs. Five to 6 gram portions of minced embryo were 
placed in 50 ml beakers and enough Krebs buffer was added to bring the 
final volume to 20 ml. Following the addition of 1.0 mCi of 4-3H pro-
line and 20 µl of 1.0 M a,a-dipyridyl in ethanol, the mixture was incu-
bated for 2 hours at 37°C under o2-co2 (95/5%) in a metabolic shaker. 
After two hours, the embryo minces were centrifuged at 30,000 rpm for 
90 minutes and the supernates discarded. Newly synthesized collagen 
was extracted from the pellet with 0.5 M acetic acid (2 ml/g tissue) 
overnight at 4°C. After centrifugation for 90 minutes at 30,000 rpm, 
aNaCl, 1.285 g; KCl, 0.224 g; MgS04 , 0.144 g; CaC12 , 0.1444 g; KH2Po4 , 0.544 g; NaHco3 , 2.10 g; D-glucose, 1.80 g; and distilled water to 1 liter. 
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the supernate containing newly-formed, unhydroxylated collagen was 
dialyzed against 10 volumes of 0.01 M Tris HCl buffer (pH 7.4) with at 
least four changes. The substrate was then autoclaved for 15 minutes 
and redialyzed against three changes of 10 volumes of Tris HCl buffer 
(pH 7.4). Substrate was then calibrated for specific activity and line-
arity with a standard purified rabbit enzyme (Chichester et al., 1976) 
and frozen in 10 ml aliquots. 
Prolyl Hydroxylase Activity 
Immediately after rats were sacrificed, livers were removed and 
40-50 mg aliquots of tissue were homogenized in 600 µl of buff er con-
-5 -5 taining 0.25 M sucrose, 10 M disodium EDTA, 10 M dithiothreitol, 
and 0.1% Triton. Prolyl hyroxylase activity in 50 and 100 µl aliquots 
of homogenate was determined by the method of Hutton et al. (1966) with 
some modifications. Aliquots of liver homogenates were incubated at 
30°C for 30 minutes in a mixture containing approximately 600,000 cpm 
(depending on substrate batch) of tritiated collagen substrate (O.l ml), 
1.0 mM ascorbate, 0.1 mM ~-ketoglutarate, 0.1 mM ferrous ammonium sul-
fate, 0.05 M Tris CHl buffer (pH 7.4), 0.2% bovine serum albumin and 
0.04% catalase. The prolyl hydroxylase reaction was stopped after 30 
minutes by the addition of 0.1 volume 50% trichloracetic acid. Tritia-
ted water was then collected by vacuum distillation; a measured frac-
tion of tritiated water was counted for radioactivity in a Packard Tri-
Carb Liquid Scintillation Spectrometer (Model 3310). This radioactivity 
reflects the stoichiometric formation of hydroxyproline and tritiated 
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water by prolyl hydroxylase in the presence of cofactors and labelled 
substrate as described above (Rhoads and Udenfriend, 1970). Due to 
variability in substrate batches, a conversion factor, derived from sub-
strate calibration with standard enzyme, was employed to permit compar-
isons of prolyl hydroxylase activity values when different substrate 
preparations are used. Values were then converted to International 
Units which are defined as "that quantity of enzyme that will catalyze 
the reaction of one µmole of substrate per minute" (Kachmar and Moss, 
1976). 
In Vitro Collagen Biosynthesis 
Collagen and noncollagen protein synthesis by liver tissue in vitro 
was determined by the method of Diegelmann et al. (1975) with modifica-
tions. Approximately 20 mg of freshly dissected liver minces were incu-
bated for 24 hours at 37°C under o2-co2 (95/5%) in 4 ml of Dulbecco's 
3 Modified Eagles medium (DME) containing 2,3- H-proline (50 µCi/ml), 
0.56 mM ascorbate, and 0.71 mM S-aminopropionitrile. Experiments have 
been conducted confirming that label incorporation into collagen and 
noncollagen protein is linear against time between 6 and 24 hours; the 
percent label in collagen does not change during this 24 hours (Mann et 
al., 1979). The incubation mixture was frozen, thawed, and homogenized 
in a Bellco glass/glass homogenizer. It was then dialyzed against 100 
volumes of 0.5 M acetic acid, containing 10-5 M disodium EDTA, with two 
changes and against 100 volumes of 0.05 M Tris HCl buffer (pH 7.4), 
24 
containing 2.5 mM n-ethylmaleimide, with two changes to remove unincor-
porated labelled proline. Tubes of 0.4 ml aliquots of sample were then 
incubated for 18 hours at 37°C in a mixture containing 0.05 Tris HCl 
buffer (pH 7.4), 2.5 mM n-ethylmaleimide, 0.5 mM calcium chloride, 0.1 
mL chloroform and 130 units of bacterial collagenase in a final volume 
of 1.0 ml. Duplicate tubes were incubated without collagenase. 
Following incubation, the reaction was stopped and protein was copreci-
pitated with 0.1 volume bovine serum albumin (1.0%) by the addition of 
one volume 10% trichloroacetic acid. After 30 minutes on ice, samples 
were centrifuged at 5,000 rpm for 30 minutes. The pellet was digested 
R in 2 ml Digestol (Yorktown, Hackensack, NJ) and counted in 10 ml 
R Hydromix scintillation cocktail (Yorktown, Hackensack, NJ), The 5% 
trichloroacetic acid supernate was again coprecipitatea using bovine 
serum albumin (1.0%) and counted in 10 ml HydromixR. Protein content 
was determined on liver homogenates. Collagen and noncollagen protein 
synthesis per unit protein were calculated from collagenase-digested 
protein in the supernate and collagenase-resistent protein in the 
pellet, respectively. Relative collagen synthesis was calculated using 
a formula which accounted for the relative enrichment of collagen pro-
line/hydroxyproline content (5.4 times) compared to noncollagen protein 
as follows (Diegelmann et al., 1975): 
% collagen 
synthesis 
= cpm in supernate x 100 (cpm in pellet x 5.4) + (cpm in supernate) 
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Protein Determination 
Protein content was determined by the method of Lowry et al., 
(1951) using bovine serum albumin as the protein standard. The inten-
sity of the characteristic blue color was read at 750 m~ on a Gilford 
250 Sprectrophotometer. 
Serum Alanine Transaminase 
Serum alanine transaminase was determined by the method of 
Reitman and Frankel (1957). Serum (0.2 ml) was incubated at 37°C for 
30 minutes with 1.0 ml substrate containing 2.0 µmoles/ml a-ketoglutar-
ate and 200 µmoles/ml alanine. One ml of 2,4-dinitrophenylhydrazine 
(1.0 µmole/ml) was added to each tube and samples were left at room 
temperature for 20 minutes after which 10 ml of 0.4 M NaOH was added. 
Following 30 minutes for color development, absorbance at 520 mµ was 
determined. Both reagent and serum blanks were prepared and all samples 
compared to a standard curve ranging from 0-1.0 µmoles of pyruvate. 
Values were then converted to International Units. 
Serum Alkaline Phosphatase 
Alkaline phosphatase in serum was determined by the two-point 
modification (Kachamar and Moss, 1976) of McComb and Bowers' (1972) 
continuous monitoring procedure with some additional modifications. 
Serum (20 µl) was incubated for 30 minutes at 37°C with 0.5 ml of 
buffered substrate containing 14.0 mM p-nitrophenylphosphate and 0.5 
mM MgC1
2 
in 0.625 M 2-amino-2-methyl-l-propanol {pH 10.25). After 30 
minutes, five ml of 0.05 M NaOH were added to each tube. Duplicate 
tubes {blanks) were prepared with the addition of serum as the final 
step. Absorption for test and blank tubes was determined at 405 mµ 
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for calculation of tJ.A (A A. ) test - -olank • The absorption differences were 
compared to a standard curve determined using p-nitrophenol; values 
ranged from 0.45 to 3.15 µmoles p-nitrophenol. Values were then con-
verted to International Units. 
Leucocyte Determination 
The number of leucocytes in whole blood was determined by dilution 
of 0.1 ml of whole blood in 1.1 ml of 0.5% acetic acid containing gen-
tian violet and quantitation in a hemocytometer chamber. 
Lectin-dependent Lymphocyte-mediated Cytolysis 
Lectin-dependent lymphocyte-mediated cytolysis was determined by 
the method of Davignon and Laux (1978). Effector cells were prepared 
from spleens removed from control and DBT-treated rats. These were 
kept at 4°C in RPMI 1640 complete for no longer than 2 hours prior to 
assay. A crude preparation of lymphocytes was expressed from spleens 
with a rubber policeman. Cells were washed and then resuspended in 
medium containing 0.83% ammonium chloride in 0.01 Tris base to lyse red 
blood cells. The remaining cells were washed three times and resuspen-
ded in medium at a concentration of 5 x 106 cells/ml. 
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51 Cr-target cells were prepared from an intraperitoneal inoculum 
b 
of EL4 leukemic cells in syngeneic mice (C56BL/6[H-2 ]). These cells 
(5-10 x 106) were incubated for 60 minutes at 37°C with 100 µCi of 
sodium chromate. 
Samples were prepared and incubated for 4 hours in a reaction mix-
5 4 ture containing 5 x 10 effector cells, 2 x 10 target cells, and 1.0 µg 
of phytohemagglutinin (PHA) or concanavalin A (Con A) in a final volume 
of 0.3 ml. Spontaneous lysis and 100% lysis were determined by replac-
ing effector cells with medium and distilled water, respectively. After 
incubation, each mixture was diluted to 2.0 ml with RPMI 1640 and 1.0 ml 
was counted in a Beckman Gamma 300 Counter. Percent lysis was calcula-
ted with the following formula: 
Percent 
Ly sis = 
Sample 
Ly sis 
100% 
Lysis 
Spontaneous 
Lysis 
Spontaneous 
Lysis 
Delayed Hypersensitivity 
Rats were tested for delayed-type hypersensitivity to DBT by foot-
pad injection (Turk, 1980). 
DBT was prepared for foot-pad injection by dissolving in ethanol 
(100 mg DBT/ml) and adding to 0.25 M sucrose with 0.05 M Tris HCl 
(pH 7.5) for final concentrations of 5 mg DBT/ml and 5% ethanol. Liver 
was prepared for injection by homogenizing 1.0 g tissue in 5.0 ml 0.25 
M sucrose/0.05 M Tris HCl (pH 7.5), adding ethanol, and diluting to a 
final concentration of 20 mg liver/ml and 5% ethanol. Liver conjugated 
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with DBT was prepared by incubating a mixture of DBT (5 mg/ml) and liver 
(2a mg/ml) in a.25 M sucrose/a.a5 M Tris HCl (pH 7.5) for 1 hour at 4°C. 
Binding of DBT to liver was established by dialyzing preparations 
of liver, DBT, and DBT/liver, similar to those described above, against 
a.as M Tris HCl (pH 7.5) with two changes and quantitating retained DBT 
by atomic absorption spectrophotometry (Perkin Elmer Model 46a Atomic 
Absorption Spectrophotometer). DBT/liver samples were also dialyzed in 
the presence of dimercaprol (12 mg/ml) to assure that the DBT was per-
meable to the dialysis tubing in spite of its relative insolubility. 
Samples were prepared for spectrophotometric analysis according to the 
method of Murthy et al. (1973) by digestion in concentrated nitric acid 
until clarity, evaporation to near dryness, and dilution in 5% nitric 
acid. Tin metal dissolved in la% HCl was used as a standard. 
Delayed-type hypersensitivity was determined by challenging control 
and DBT-treated rats with a.1 ml vehicle, liver, DBT, or DBT/liver in 
the right foot-pad 13 days after the start of DBT treatment. Foot-pad 
swelling was assessed by volume displacement, using a solution of 
Wright's stain for visibility, and right/left foot volume ratios were 
calculated. 
Immunofluorescence 
Direct inununofluorescence (Kawamura, 1977) against rat IgG was 
performed on control and DBT-treated rat livers using Raine's variation 
of this standard method (personal communication). Frozen sections were 
prepared from fresh liver and cut at 4 µ. Tissue was placed in acetone 
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for 10 minutes, 95% ethanol for 20 minutes, and rinsed twice in phos-
phate buffered saline. Duplicate slides were incubated with control 
rat serum for 30 minutes at room temperature after which all slides 
were incubated for 30 minutes at room temperature with fluorescented 
rabbit anti-rat IgG (F/P = 4.1). After rinsing twice with phosphate 
buffered saline, slides were coverslipped with Aqua MountR (Lerner Labs, 
Stamford, CT), nonfluorescing medium. 
Statistical Methods 
Statistical analyses performed included Students' t-test, linear 
regression, analyses of variance (one-way and multifactorial classifi-
cations), and Newman Keuls pairwise comparisons. Acceptable level for 
a test of significance in these studies was at P<0.05. Formulae appli-
cable to these analyses follow: 
a) Mean = x = Ex/n 
b) Variation= E(x-X) 2 = Sum of Squares = SS 
c) Variance = E(x-x) 2 = Mean of Squares = MS 
d) Standard Deviation = s = ~ v~ 
e) Standard Error of x = sx = s/A[D. = SEM 
f) Regression Equation = yx = a + bx 
g) Correlation Coefficient = r =J7 :j-1 - _r. _CY_-_Y x_)_2 
E (y-Y)2 
h) 
i) 
j) 
i) 
* 
Students' t statistic = t = xl - X2 
J ss1 + ss2 1 + 2 -nl + n2 - nl 
Studentized Range Statistic = q = T large T small 
1} MSerror/n 
* One-way Analysis of Variance (ANOVA) 
SS df 
2 2 k-1 Between L:T. /n-G /kn 
J 
Within 2 2 k(n-1) Hx. -L:T. /n 
J J 
Total 2 2 Hx. -G /kn kn-1 
J 
F [k-1,k(n-l)] 
* 2 x 2 Analysis of Variance (ANOVA) 
SS 
A 2 2 L:A /nq-G /npq 
B 2 2 L:B /np-G /npq 
AB 2 2 2 2 L:(AB) /n-L:A /nq-L:B /np+G /npq 
Error 2 2 HL:x -L: (AB) /n 
Total 2 2 HL:x -G /npq 
MS 
SS/k-1 
SS/k(n-i) 
SS/kn-1 
df 
p-1 
q-1 
(p-1) (q-1) 
pq(n-1) 
pqn-1 
FA= MSA/MSE 
FB = MSB/MSE 
FAB = MSAB/MSE 
F[p-l,pq(n-1)] 
F[q-1,pq(n-l)] 
F[(p-l)(q-1),pq(n-l)] 
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1 
n2 
F 
MSbe/MSWI 
MS 
SS/p-1 
SS/q-1 
SS/(p-l)(q-1) 
SS/pq(n-1) 
SS/pqn-1 
The necessary corrections for unequal n were made by Statistical 
Analysis Systems (SAS), University of Rhode Island. 
RESULTS 
0 to 4 Day Studies 
Since prolyl residues have been shown to be hydroxylated subsequent 
to incorporation into procollagen (Prockop and Juva, 1965) and such 
hydroxylation does not occur to a significant extent in noncollagen pro-
tein, prolyl hyroxylase activity (PHA) can be used as a measure of col-
lagen synthesis in rat liver. The effect of DBT administration from 0 
to 4 days on PHA in rat liver homogenates is shown in Figure 1. There 
was a gradual increase in activity reaching greater than 220% of control 
by day 4. 
Although PHA has been shown to be a sensitive indicator of collagen 
synthesis in the liver (Mann et al., 1979), a more direct indication of 
absolute and relative collagen synthesis is obtained by measurement of 
in vitro incorporation of 3H-proline into collagenase-degradable and 
collagenase-resistant protein (Diegelmann et al., 1975). A gradual 
increase in collagen synthesis, reflected by 2,3-3H-proline released 
from liver protein by collagenase, was observed from 0 to 4 days of DBT 
administration reaching approximately 500% of control by day 4 (Figure 
2). This was not accompanied by an increase in noncollagen synthesis, 
as measured by incorporation of 2,3-3H-proline into collagen-resistant 
protein. There was a significant correlation (r=0.94) between the acti-
vity of prolyl hydroxylase and in vitro collagen synthesis (Figure 3). 
Since elevated serum alanine transaminase is commonly associated 
with hepatic inflammation (DeRitis et al., 1965), the activity of this 
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Figure 1. 
EFFECT OF DIBUTYLTIN'1 (DBT) ON HEPATIC PROLYL HYDROXYLASE ACTIVITYb IN 
RATS AFTER 0 TO 4 DAYS OF TREATMENT. 
a) DBT in corn oil was administered at a dose of 20 mg/kg/day, p.o.; 
controls received equivalen amounts of corn oil. 
b) Enzyme activity in liver homogenates was quantitated by tritium 
release assay from labelled collagen substrate as described in the 
methods. Seven experimental animals were used per day. Values are mean 
+ S.E.M. Analysis of variance, one-way classification for the treatment 
variable day, significant at P<0.05. 
c) Significant at P<0.05 vs. control (Newman Keuls pairwise comparisons). 
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Figure 2. 
EFFECT OF DIBUTYLTINa (DBT) ON IN VITRO COLLAGEN AND NONCOLLAGEN PROTEIN 
SYNTHESISb IN RAT LIVER AFTER 0 TO 4 DAYS OF TREATMENT. 
a) DBT in corn oil was administered at a dose of 20 mg/kg/day, p.a.; 
controls received equivalent amounts of corn oil. 
b) Collagenase digestion was performed on homogenates of liver minces 
3 following 24 hour incubation with 2,3- H-proline as described in the 
methods. Collagen is represented by label in supernate as a result of 
collagenase digestion. Noncollagen protein is represented by labelled 
collagenase-resistant protein in the pellet. Three experimental animals 
were used per day except for control where two were used. Values are 
mean + S.E.M. Analysis of variance, one-way classification for the 
treatment variable day, significant at P<0.05 for the response variable 
collagen. 
c) Significant at P<0,05 vs. control and day 1 (Newman Keuls pairwise 
comparisons). 
-~ 
-z 
w 
I-
0 
f 
0 
E 
....... 
~ 
ti. g 
w 
z 
::i 
0 
er 
ti. 
,..., 
:c 
u. 
,,, 
N' 
• 3)0 
200 
100 
1'! 2,3 [3t-f J PROUNE RELEASED FROM 
LJ LIVER PROTEIN BY COLLAGENASE 
D 2,3 [~] PROUNE INCORPORATED INTO COLLAGENASE- RESISTANT PROTEIN 
0 2 3 
DAYS OF TREATMENT 
33 
c 
40 
-g 
-z 
jjj 
5 
er 
30 ti. 0 
E 
,,, ....... 
'o 
x 
~ 
ti. 
(.) 
-w 
z 
::i 
0 
er 
ti. 
.... 
~ 
~ 
""~ N 
4 
Figure 3. 
CORRELATION BETWEEN HEPATIC PROLYL HYDROXYLASE ACTIVITY AND IN VITRO 
COLLAGEN SYNTHESISa. 
a) Each point represents mean+ S.E.M. of prolyl hydroxylase activity 
and in vitro collagen synthesis on the specified day of treatment. 
Experimental details are described in Figures 1. and 2. and the methods. 
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enzyme was determined in serum from rats after 4 days of DBT administra-
tion. An increase in serum alanine transaminase of approximately 400% 
of control was observed at this time (Table 1). 
Histological observations of livers from rats treated with DBT for 
0 to 4 days revealed increasing frequency of the appearance of peripor-
tal inflammation and bile duct proliferation during this period (Figures 
5 and 6) as compared to control (Figure 4). The infiltration of pre-
dominantly polymorphonuclear cells was extensive in the proximity of 
ductular cells. 
12-Day Studies 
The effect of DBT on parameters of hepatic collagen metabolism 
after 12 days of treatment is shown in Table 2. These results have 
been described previously (Yermakoff, 1978). The activity of prolyl 
hydroxylase was increased to nearly 150% of control in DBT-treated rats. 
There was no significant change in either the amount of label released 
from liver protein by collagenase or the amount incorporated into colla-
genase-resistant protein. However, the percent of total labelled pro-
tein digested by collagenase was increased approximately two-fold in 
animals treated with DBT, reflecting a change in these two parameters 
relative to each other. Finally, DBT produced a greater than two~fold ­
increase in hepatic hydroxyproline content, representing an increase in 
collagen accumulation. 
Since certain serum enzymes have been shown to be useful indicators 
of both the degree and type of liver injury (DeRitis et al., 1965), 
Table 1. Effect of dibutyltin dichloridea (DBT) on serum alanine 
transaminaseb (ALTA) after 4 days of treatment. 
Group 
Control 
DBT 
No. of 
Rats 
6 
5 
ALTA 
(mIU /0. 2ml) 
6.18 + 0.32 
23.00 + 3.44c 
aoBT was administered at a dose of 20 mg/kg/day, p.o.; controls 
received equivalent amounts of corn oil. 
bserum ALTA was determined colorimetrically as described in the 
methods. Values are mean + S.E.M. 
csignificant at P < 0.05 vs. control (two-tailed Student's t-test). 
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Figure 4. 
PHOTOMICROGRAPH OF LIVER FROM A CONTROL RAT SHOWING A CENTRAL VEIN AND 
PORTAL TRIAD. TRICHROME STAIN x 100. 
37 
Figure 5. 
RAT LIVERS AFTER 1 DAY (A) AND 2 DAYS (B) OF DBT ADMINISTRATION 
(20 mg/kg/day, p.o.). PERIPORTAL INFLAMMATION AND DISORGANIZATION OF 
DUCTULAR CELLS ARE APPARENT IN (B), TRICHROME STAIN x 100, 
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Figure 6. 
PHOTOMICROGRAPH OF RAT LIVERS AFTER 3 DAYS (A) AND 4 DAYS (B) OF DBT 
ADMINISTRATION (20 mg/kg/day, p.a.). DISORGANIZED DUCTULAR CELL PRO-
LIFERATION AND PERIPORTAL INFLAMMATION ARE SEEN IN (A) AND, MORE PERVA-
SIVELY, IN (B). TRICHROME STAIN x 100. 

Table 2. Effect of dibutyltin dichloridea (DBT) on parametersb of 
hepatic collagen metabolism after 12 days of treatment. 
Prolyl Hydroxylase Activity 
(mU/mg protein) 
In Vitro Collagen Synthesis 
4-3H-proline released from liver 
protein by collagenase 
(cpm/mg protein) 
4-3H-proline incorporated into 
collagenase resistant protein 
(cpm x 10-3/mg protein) 
% total labelled protein digested 
by collagenase 
Hydroxyproline Content 
(ug/g liver wet weight) 
Control 
0.282 + 0.010 
(10) 
307 + 81 
(6) 
19.2 + 3.0 
(6)_ 
0.30 + .0.08 
(6) 
125 + 4 
(6) 
DBT 
0.412 + o.029c 
(12) 
440 + 75 
(5) 
13.4 + 0.9 
(5) 
0.59 + 0.08C 
(5) 
266 + 4c 
(6) 
aDBT was administered in corn oil 20 mg/kg, q.o.d., p.o.; controls 
received equivalent amounts of corn oil. 
bnata and methods have been described previously (Yermakoff, 1978). 
Values are mean+ S.E.M. 
csignificant vs. control at P < 0.05 (two-tailed Student's t-test). 
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alanine transaminase and alkaline phosphatase activities were determined 
in serum from DBT-treated rats after 12 days of administration. There 
was no significant elevation in the activity of either of these two 
enzymes in treated animals (Table 3). 
Histological changes in these rats included extensive infiltration 
of both polymorphonuclear and mononuclear cells, proliferation and in-
jury to ductular cells, and fibrosis within the portal tracts (Figures 
7 and 8). 
The effect of the nonsteroidal antiinflammatory drug, naproxen, on 
the activities of prolyl hydroxylase and alanine transaminase when admi-
nistered alone and in combination with DBT for 12 days is shown in 
Figure 9. DBT produced an increase in PHA which was 146% of control, 
while naproxen had no significant effect on the activity .of this enzyme. 
Naproxen and DBT administered together produced an increase in PHA that 
was 127% of control. The interaction between these two compounds was 
not significant as measured by multifactorial analysis of variance with 
the treatment variables DBT and naproxen. However, there was no signi-
ficant difference between PHA in the naproxen and DBT/naproxen groups. 
The activity of serum alanine transaminase was not elevated in any 
group. 
Age-related Studies 
Since DBT has been shown to produce thymotoxicity and impaired 
cell-mediated immunity in rats treated with DBT pre- and postnatally 
(Seinen et al., 1977b) and immunologic processes were suspected in 
Table 3. Serum enzymes after 12 days of dibutyltin dichloridea (DBT) 
administration. 
Group 
Control 
DBT 
Alanine Transaminaseb 
Activity (mIU/0.2ml) 
4. 98 + o. 25 (7) 
6.26 + 1.05 (9) 
Alkaline Phosphataseb 
Activity (mIU/ml) 
266 + 19 (8) 
268 + 27 (10) 
aDBT was administered at a dose of 20 mg/kg, q.o.d., p.o.; controls 
received equivalent amounts of corn oil. 
bEnzyme activity was determined colorimetrically as described in the 
methods. Values are mean+ S.E.M. 
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Figure 7. 
A PORTAL TRACT AFTER 12 DAYS OF DBT ADMINISTRATION (20 mg/kg/day, 
p.a.). FIBROUS TISSUE SURROUNDS THE PORTAL VEIN. PERIPORTAL INFLAMMA-
TION IS EXTENSIVE AND DISORGANIZED DUCTULAR CELL PROLIFERATION IS APPAR-
ENT. TRICHROME STAIN x 100. 
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Figure 8. 
PORTION OF A PORTAL TRACT AFTER 12 DAYS OF DBT ADMINISTRATION (20 mg/kg, 
q.o.d., p.o.). INFLAMMATORY CELLS SURROUND INJURED AND PROLIFERATING 
DUCTULAR CELLS. TRICHROME STAIN x 100. 
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Figure 9. 
EFFECTS OF DIBUTYLTINa (DBT) AND NAPROXENa (NAP) SEPARATE AND COMBINED 
ON HEPATIC PROLYL HYDROXYLASE ACTIVITYb AND SERUM ALANINE TRANSAMINASE 
ACTIVITYc IN RATS AFTER 12 DAYS OF TREATMENT. 
a) DBT and NAP were administered in corn oil at doses of 20 mg/kg, 
q.o.d., p.a., and 15 mg/kg, b.i.d., p.a., respectively; controls 
received equivalent amounts of corn oil. 
b) Prolyl hyroxylase activity (FHA) was determined in liver homogen-
3 
ates by H-release assay from labelled collagen substrate as described 
in the methods. 
c) Serum alanine transaminase activity (ALTA) was determined colori-
metrically as described in the methods. All values are mean+ S.E.M. 
d) Analysis of variance, multifactorial classification for the treat-
ment variables DBT and NAP and the response variable PHA or ALTA, 
significant effect at P<0.05. 
e) Analysis of variance, one-way classification for the treatment vari-
able DBT and the response variable PHA or ALTA, significant at P<0.05. 
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DBT-induced cholangitis, a possible inverse relationship between these 
two phenomena was investigated in age-related studies. The effect of 
DBT on hepatic PHA after 12 days of treatment invarious age groups is 
shown in Table 4. Enzyme activity was 125%, 146%, and 215% of control 
in rats 4, 9, and 14 weeks of age at the start of treatment. Quantita-
tion of peripheral blood leucocytes, presented in Table 5, shows a DBT-
induced elevation in these cells only in the rats 9 and 14 weeks of age 
at the start of treatment. The effects of DBT on rat body weight in 
these three age groups is compared in Figure 10; there was a significant 
difference between control and DBT-treated animals in the 9 and 14 week 
groups only. 
Hepatic histopathology in rats 14 weeks of age at the start of treat-
ment was similar to that observed in the 9-week old group, which was 
described above. However, the 4-week old group showed little evidence 
of the usual histopathalogic lesions induced by DBT. Periportal inflam-
mation and bile duct proliferation were moderate or absent in these 
livers (Figure 11). 
Immunolosi 
Since DBT has been shown to produce thymotoxicity in weanling rats 
following both intravenous administration or incorporation of DBT in 
the diet (Seinen et al., 1977b), the effect of DBT on thymus weight in 
4-week old rats in the dosage regimen described herein was investigated. 
Table 6 shows a striking decrease in thymus weight to less than one 
Table 4. Effect of dibutyltin dichloridea(DBT) on prolyl hydroxylase 
activityb(PHA) after 12 days of treatment in rats 4,9, and 
14 weeks of age at the start of treatment. 
No. of 
Group Rats 
4 
Control 6 
DBT 10 
9 
Control 10 
DBT 12 
14 
Control 4 
DBT 8 
PUA 
(mU/mg protein) 
WEEKS 
0.307 + 0.018 
0.386 + o.014c 
WEEKS 
0.282 + 0.010 
0.412 + o.029c 
WEEKS 
0.136 + 0.016 
0.292 + o.044c 
% 
Control 
100 + 6 
125 + 5c 
100 + 4 
146 + 10c 
100 + 12 
215 + 32c 
aDBT was administered at a dose of 20 mg/kg, q.o.d., p.o.; controls 
received equivalent amounts of corn oil. 
bpHA was determined in liver homogenates by the 3H-release assay from 
labelled collagen substrate as described in the methods. Values are 
mean+ S.E.M. 
csignificant at P < 0.05 vs. control (one-tailed Student's t-test). 
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Table 5. Effect of dibutyltin dichloridea(DBT) on leucocyte countb 
after 12 days of treatment in rats 4, 9, and 14 weeks of 
age at the start of treatment. 
Group 
Control 
DBT 
Control 
DBT 
Control 
DBT 
No. of 
Rats Leucocytes/cu min 
4 W E E K S 
5 6,450 + 507 
9 5,183 + 793 
9 WE E K S 
5 12,130 + 1,142 
5 18,940 + 2,379 
1 4 W E E K S 
4 
7 
9,700 + 1,236 
12 ,114 + 709 
% 
Control 
100 + 8 
80 + 12 
100 + 9 
156 + 19 
100 + 13 
125 + 7 
aDBT was administered at a dose of 20 mg/kg, q.o.d., p.o.; controls 
received equivalent amounts of corn oil. 
bLeucocytes were quantitated as described in the methods. Values 
are mean + S.E.M. 
cSignificant at P<0.05 vs. control (one-tailed Student's t-test). 
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Figure 10. 
EFFECTS OF DIBUTYLTI~ (DBT) ON RAT BODY WEIGHTb AFTER 12 DAYS OF 
TREATMENT. 
a) DBT in corn oil was administered at a dose of 20 mg/kg, q.o.d., p.o.; 
controls received equivalent amounts of corn oil. 
b) The number of experimental animals in each group are shown in paren-
theses. Values are mean+ S.E.M. of weight change during DBT treatment. 
c) Significant at P<0.05 vs. control (one-tailed Students' t-test). 
D CONTROL 
~ DST, 20mg /kg, q.o.d., p.o. 
+roo 
+ 80 
w + 60 (.!) 
z 
cl: 
I + 40 (.) 
I-
I 
(.!) + 20 w 
~ 
0 
- 20 c 
- 40 c 
( 6) (10) (II) (17) (4) (9) 
4 WEEKS S WEEKS 14 WEEKS 
AGE AT ST ART OF TREATMENT 
49 
Figure 11. 
LIVER FROM 4-WEEK OLD RAT AFTER 12 DAYS OF DBT ADMINISTRATION 
(20 mg/kg, q.o.d., p.o). TRICHROME STAIN x 100. 
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a 
Table 6, Effect of DBT on thymus weight in rats 4 weeks of age, 
No. of Thymus Thymus Body Weight · Thymus 
Rats (g dry weight) (g wet weight) (g) (mg/g body weight) 
Control 6 0.15 + 0.02 0.82 + 0.11 182 + 14 4.4 + 0.4 
DBT 10 0,04 + 0.01 b 0.25 + 0.04 b 191 + 6 1.3 + 0.2 
~BT in corn oil was administered 20 mg/kg, q.o.d., p.o. for 12 days; controls received 
equivalent amounts of corn oil. Values are mean + S.E.M. 
b P<0,05 vs. control (two-tailed Student's t-test). 
b 
Vl 
...... 
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third of control when measured by wet or dry organ weight. When normal-
ized for body weight, the decrease in thymus weight is as great. 
Immunologic studies of 9-week old rats included determination of 
lectin-dependent lymphocyte-mediated cytolysis (Davignon and Laux, 1978). 
The assay is a measure of cytotoxic t-cell activity, in which the pre-
sence of lectin precludes the requirement for specific target cells. 
51 Lysis of Cr-labelled target cells by cytotoxic t-cells was not appar-
ent in either control or DBT treated rats after 12 days of treatment. 
Percent lysis was approximately 0-2% in both groups. 
A second parameter of cell-mediated immunity, delayed-type hyper-
sensitivity, was investigated in rats after 12 days of DBT administra-
tion. Challenge doses of DBT were given with this organotin alone or 
conjugated to a liver macromolecule. Equilibrium analysis studies con-
firmed that most of the DBT (94%) in this DBT/liver conjugate is non-
dialyzable after incubation with liver homogenate as compared to 48% 
and 42% without liver and in the presence of dimercaprol, respectively. 
After a challenge dose of DBT or DBT/liver conjugate, both controls and 
DBT-treated rats showed foot-swelling characteristic of a delayed-type 
hypersensitivity response (Table 7). However, the equivalent responses 
in control and treated animals suggested that these results were not due 
to an innnunologic response. Histopathologic observation revealed pre-
dominately polymorphonuclear infiltration and extensive tissue injury 
suggesting acute inflammation (Figure 12). 
Investigation of antibodies directed against hepatic antigens and/or 
DBT in liver from DBT-treated rats was performed by direct immunofluor-
escence using rabbit anti-rat IgG. Immunofluorescence was localized to, 
Table 7. Effect of a challenge dosea of dibutyltin (DBT) on rats 
after 12 days of DBT administrationb. 
Challenge Ratio Right/Left Foot Volume 
CONTROL DBT 
Vehicle 
Liver 
(2 mg) 
DBT 
(0.5 mg) 
DBT/Liver 
(0.5 mg/2 mg) 
1.0 1.0 
1.0 1.0 
1.0 1.0 
1.0 1.0 
1.0 1.0 
1.0 1.0 
1.3 1.3 
1. 3 1.5 
1.3 2.3 
1.8 1.8 
1.8 1. 7 
1.8 1.3 
aChallenge dose contained the concentrations of DBT and liver 
indicated above in a volume of 0.1 ml; it was injected in the 
right foot pad using a 1/4 cc glass syringe and 25 gauge needle. 
bDBT was administered at a dose of 20 mg/kg, q.o.d., 
controls received equivalent amounts of corn oil. 
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p. 0.; 
Figure 12. 
MUSCLE FIBERS IN A NORMAL RAT FOOT (A) AND IN A FOOT 24 HOURS AFTER 
INJECTION OF 0.5 mg DBT INTO THE FOOT PAD (B). ACUTE INFLAMMATION AND 
DISORGANIZATION OF MUSCLE FIBERS ARE APPARENT IN (B). HEMATOXYLIN-
EOSIN STAIN x 400. 
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but equally intense throughout, the portal tracts. It was suggestive 
of a reaction against serum IgG rather than antibodies directed 
against a particular hepatic cell type. 
Studies with SKF 525A 
The possible relationship between differences in hepatic micro-
somal metabolism and age-related effects of DBT was investigated using 
an inhibitor of microsomal enzymes, SKF 525A. SKF 525A and DBT were 
administered alone and concomitantly to rats for 4 days. The effects 
of these treatments on PHA and serum alanine transaminase activity are 
shown in Figure 13. PHA was increased in the DBT group and SKF group 
to approximately 220% and 250% of control, respectively. The activity 
of prolyl hydroxylase in the DBT/SKF 525A group was nearly 270% of 
control and substantially less than what would be anticipated if their 
effects were additive; as determined by a multifactorial analysis of 
variance with the treatment variables DBT and SKF 525A, this represented 
a significant interactive effect between these two compounds. There was 
no difference in the protein content of liver tissue in all four groups 
when measured as mg protein/mg liver wet weight. Therefore, prolyl 
hydroxylase values in the livers of these rats were not a function of 
altered protein content. The increase in alanine transaminase activity 
measured in the serum from DBT-treated rats at 4 days time was complete-
ly inhibited by SKF 525A. 
Observation of livers from SKF 525A-treated rats revealed rela-
tively normal histology (Figure 14). The only obvious pathology was the 
Figure 13. 
EFFECTS OF DIBUTYLTINa (DBT) AND SKF 525Aa (SKF) SEPARATE AND COMBINED 
ON HEPATIC PROLYL HYDROXYLASE ACTIVITYb AND SERUM ALANINE TRANSAMINASE 
ACTIVITYc IN RATS AFTER 4 DAYS OF TREATMENT. 
a) DBT in corn oil was administered at a dose of 20 mg/kg/day, p.o. 
and SKF in saline at a dose of 50 mg/kg, b.i.d., i.p.; controls received 
equivalent amounts of vehicles. 
b) Prolyl hydroxylase activity (PHA) was determined in liver homogen-
3 
ates by H-release assay from labelled collagen substrate as described 
in the methods. 
c) Serum alanine transaminase activity (ALTA) was determined colori-
metrically as described in the methods. Values are mean + S.E.M. 
d) Analysis of variance, multifactorial classification for the treat-
ment variables DBT and SKF and the response variable PHA and ALTA, 
significant effect at P<0.05 or 
e) significant interaction at P<0.05. 
f) Analysis of variance, one-way classification for the treatment vari-
able DBT and the response variable PHA or ALTA, significant at P<0.05. 
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Figure 14. 
LIVER FROM A RAT TREATED WITH SKF 525A (50 mg/kg, b.i.d., i.p.) FOR 4 
DAYS SHOWING FATTY INFILTRATION. TRICHROME STAIN x 100. 
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presence of fatty infiltration (Figure 15). Livers from rats treated 
with SKF 525A and DBT (Figure 16) were very similar to those in the SKF 
525A group. Fatty infiltration was evident, but periportal inflammation 
and biliary injury seen with DBT treatment alone for 4 days (Figure 6b) 
were absent. 
Figure 15. 
FATTY INFILTRATION IN LIVER PARENCHYMAL CELLS AFTER 4 DAYS OF SKF 
ADMINISTRATION (50 mg/kg, b.i.d., i.p . ) . TRICHROME STAIN x 400. 
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Figure 16. 
PORTION OF A PORTAL TRACT IN RAT LIVER AFTER 12 DAYS OF DBT (20 mg/kg, 
q.o.d., i.p.) AND SKF 525A (50 mg/kg, b.i.d., i.p.) ADMINISTRATION. 
FATTY INFILTRATION CAN BE SEEN IN HEPATOCYTES. TRICHROME STAIN x 100. 
' 
' 
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DISCUSSION 
Administration of DBT from 0 to 4 days produces a progressive 
increase in the two parameters of hepatic collagen synthesis examined, 
prolyl· hydroxylase activity (PHA) (Figure 1) and in vitro collagen 
synthesis (Figure 2). The correlation (r=0.94) between these two 
parameters (Figure 3) substantiates the predictive value of PHA 
as an estimate of hepatic collagen synthesis. A similar correlation 
has been observed in human liver biopsies taken from patients exhib-
iting both normal and pathological histology (Mann et al., 1979). 
The increase in PHA and in vitro collagen biosynthesis from 
0 to 4 days are associated with increasing frequency and severity 
of histopathologic changes during this period (Figures 4-6). The 
periportal inflammation, present throughout most specimens by day 4, 
contains predominantly polymorphonuclear cells and is, therefore, 
suggestive of acute inflammation. Proliferated bile ducts are often 
seen in the inflammatory area. Such proliferation is associated with 
many types of liver injury and is considered a characteristic feature 
of the fibrotic/cirrhotic process (Masuko et al., 1964). Although 
histologic evidence of fibrosis in these livers is moderate at best, 
biochemical data indicate that fibrogenic processes are active after 
4 days of DBT treatment. 
Serum alanine transaminase is elevated approximately four-fold 
in rats treated with DBT for 4 days. Since increased serum a.lanine 
transaminase reflects parenchymal liver injury (Kachmar and Moss, 1976) 
61 
and such injury is very rarely observed in livers from DBT-treated 
rats unless it is proximal to inflannnatory areas, this increase in 
serum enzyme activity is probably a function of the inflammatory 
process in the liver. 
After 12 days of DBT administration, increases in hepatic PHA, 
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in the percent of in vitro protein synthesis directed toward collagen, 
and in liver hydroxyproline content are observed (Table 2). The 
increase in the activity of prolyl hydroxylase is less than that 
observed after 4 days of DBT treatment (146% vs. 221%). This is not 
indicative of reversal of liver injury. Rather, PHA has been shown 
to be an early indicator of increased hepatic collagen synthesis 
both in human liver disease (Mann et al., 1979) and in carbon tetra-
chloride-induced experimental liver injury (Lindblad and Fuller, 1980). 
The approximately two-fold increase in the percent of labelled 
protein digested by collagenase appears to be the result of a small 
increase in the amount of label released from liver protein by col-
lagenase relative to decreased incorporation into collagenase-resistant 
protein; the changes in these latter two parameters, when considered 
alone, are not statistically significant. The increase in histologi-
cally demonstrable fibrosis after 12 days of DBT administration 
suggests that the increase in the percent in vitro collagen synthesis 
is due to replacement of viable parenchyma with areas of connective 
tissue and collagen-producing cells. Such connective tissue accumula-
tion is also apparent from the increased hydroxyproline content in 
these livers. 
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Neither of the serum enzyme activities measured in rats after 12 
days of DBT administration are significantly elevated above control 
values (Table 3). Since serum alanine transaminase activity usually 
reaches peak levels early in liver injury (Kachmar and Moss, 1976), 
the low levels of this enzyme at this time are not surprising. 
Large increases in serum alkaline phosphatase are observed in 
both humans (DeRitis et al., 1965) and rats (Kaplan and Righetti, 1970) 
as a result of cholestasis. This increase in serum alkaline phospha-
tase is thought to be a result of de novo synthesis by the liver of 
an isoenzyme of hepatic alkaline phosphatase (Kaplan and Righetti, 
1970). Since alkaline phosphatase is not elevated in serum from rats 
administered DBT for 12 days (Table 3), cholestasis does not appear 
to be a factor in the cause and/or perpetuation of DBT-induced liver 
injury at this time. Since this enzyme is inhibited by certain heavy 
metals (Kachmar and Moss, 1976), in vitro inhibition of alkaline phos-
phatase activity in control serum by DBT was investigated to ascertain 
whether such an effect could be responsible for erroneously low enzyme 
activity in DBT-treated rats; no such inhibition could be demonstrated. 
Liver histopathology after 12 days of DBT administration (Fig-
ures 7 and 8) reveals extensive periportal inflammation; both mono-
nuclear and polymorphonuclear cells are present. Ductular cell in-
jury and proliferation and fibrosis within the portal tracts are 
extensive. The central veins and parenchyma proximal to them remain 
well preserved. Although the majority of DBT-treated rats exhibit 
such a periportal lesion, a small number of animals invariably fail 
to do so. On occasion, granulomatous lesions are observed in livers 
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after 12 days of DBT treatment. 
The role of inflammation in DBI-induced fibrogenesis was investi-
gated with naproxen, a compound which has been shown to exhibit potent 
antiinflammatory and antigranuloma activity (Rook II, 1970). The 
effect of naproxen, administered alone and in combination with DBT 
for 12 days, is shown in Figure 9. As determined by a multifactorial 
analysis of variance with the treatment variables DBT and naproxen, 
there is no significant interactive effect with respect to PHA. How-
ever, when the naproxen group is compared to the naproxen/DBT group 
in a one-way analysis of variance, there is no significant difference 
between them. This suggests that DBT's fibrogenic properties are 
modified in the presence of naproxen, but that the effects of this 
antiinflammatory drug are moderate at best. There is no significant 
increase in serum alanine transaminase in any group. The decrease 
observed in the naproxen group is not meaningful on a physiological 
level. 
DBI-induced toxicity is similar in many respects to the clinical 
entity, primary biliary cirrhosis (PBC). PBC is a chronic liver 
disease typified histologically by destructive cholangitis. As such, 
the term PBC is a misnomer but has been adhered to by convention. 
PBC has been categorized as an autoimmune disease by virtue of 
antiductular cell (Paronetto et al., 1964a and 1964b) and antimito-
chondrial (Dickson et al., 1979) antibodies present in the liver. 
However, an autoimmune etiology is by no means established. 
The histological appearance of DBI-induced fibrosis, like PBC 
(Rubin et al., 1965), begins with p~riportal inflammation and bile 
duct proliferation and progresses to destructive cholangitis and, 
finally, to fibrosis in its later stages. PHA is increased in PBC 
prior to histologically demonstrable collagen accumulation (Jain 
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et al., 1978) as is seen in DBT-injured livers. Impaired cell-mediated 
immunity has been associated with PBC (MacSween and Thomas, 1973; 
Schaffner, 1979) and is produced by the administration of DBT to rats 
(Seinen et al., 1977a and 1977b). Finally, it has been suggested that 
PBC is drug-induced since this disease is associated with a history 
of drug hypersensitivity (Paronetto, 1964a). 
The similarities between PBC and DBT-induced liver injury and 
the immunologic alterations in the former raised the suspicion that 
DBT's effects on the liver might have an immunologic component. The 
i~variable failure of a small number of DBT-treated rats to respond 
with the hepatic lesions typical of DBT exposure, also suggested a 
host-dependent factor in DBT-induced injury. 
Since DBT administration to neonatal rats impairs cell-mediated 
immunity and produces thymus atrophy (Seinen et al., 1977a and 1977b) 
and thymotoxic compounds are less effective in adult animals, hepatic 
injury produced by DBT was compared in various age groups. This was 
to serve as a starting point in the investigation of a possible rela-
tionahip between impaired thymus-dependent immunity and liver injury. 
DBT administration for 12 days to rats 14 weeks of age at the start 
of treatment produces periportal fibrosis similar to that described 
above for rats 9 weeks of age. However, the 4-week-old group is 
relatively resistant. In this latter group, PHA is elevated by 125% 
of control as compared to 146% and 215% in the 9 and 14 week-old 
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groups, respectively (Table 4). Leucocytosis (Table 5) and weight 
loss (Figure 12), usually associated with DBT-induced liver injury, 
are absent in these younger rats. Liver histology in these 4-week-
old rats is similar to that seen in control animals (Figure 11). 
The age-dependent effects of DBT strengthened the suspicion that 
DBT-induced liver injury may have an immunologic component and, spec-
ifically, one that is thymus-dependent. When thymus weights were 
measured .in 4-week-old rats treated with DBT for 12 days (Table 6), it 
became apparent that DBT produces thymotoxicity in these animals 
similar to that reported in the literature for neonatal rats (Seinen 
et al., 1977a and 1977b). This thymus atrophy can not be attributed 
to dehydration since the effect is equally pronounced expressed as wet 
or dry weight. 
To determine whether the inverse relationship between DBT-
induced thymotoxicity and liver injury is related to a thymus-dependent 
immunologic component in the latter, a number of immunologic studies 
were performed on the 9-week-old rats. The assay for lectin-dependent 
lymphocyte-mediated cytolysis shows no difference between control and 
DBT-treated rats indicating that cytotoxic lymphocytes are not associ-
ated with DBT-induced liver injury. 
The test for delayed-type hypersensitivity (Table 7) shows a 
characteristic foot swelling subsequent to a challenge dose of DBT 
in both control rats and those administered DBT for 12 days. This 
suggests that an immunologic reaction is not responsible. Histologi-
cal observation of feet from control and DBT-treated rats, both of 
which were challenged with DBT, reveals no apparent differences. 
However, striking differences are observed in rats challenged with 
DBT (Figure 12b) or DBT/liver compared to vehicle (Figure 12a) or 
liver. The predominantly polymorphonuclear cell infiltration in 
Figure 12b is indicative of acute inflammation. 
Since thymotoxicity could impair hum.oral immunity through t-
helper cells, direct immunofluorescence was used to look for the 
presence of antibodies directed against DBT and/or hepatic antigens 
in livers of DBT-treated rats. The immunofluorescence observed was 
localized to, but of uniform intensity throughout, portal tracts. 
It is suggestive of a reaction against serum IgG, which is likely 
to be increased periportally due to the inflammation. The immuno-
fluorescence is not intensified at a given cell type or area within 
the portal tract. 
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No evidence for immunologic processes in DBT-induced liver injury 
is provided by these experiments. However, one can only conclude 
from these studies that an immunologic component of DBT-induced liver 
injury is not apparent at this time. If the duration of DBT exposure 
in rats could be expanded to more closely approximate drug-induced 
liver disease in humans, immunologic processes might become evident. 
One must consider that the immunologic processes seen in association 
with destructive cholangitis in human liver disease are usually 
investigated in late stages of the disease. This is due to both the 
lack of availability of liver biopsies in early stages of human 
liver disease for ethical reasons and the insidious onset of PBC 
(Dickson et al., 1979). Also, the immunologic phenomena are gener-
ally beleived to be reactive rather than eausative in destructive 
cholangitis (Popper and Schaffner, 1970) and, therefore, would be 
expected to appear in more advanced stages of such liver disease. 
Since the metabolic capabilities of the hepatic microsomal 
monooxygenase system increase with maturity (Niems et al., 1976) 
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and DBT has been shown to be metabolized by this system in rats 
(Kinnnel et al., 1977), the relationship of possible differences in 
such metabolism to the age-dependent effects of DBT was investigated. 
An inhibitor of hepatic microsomal enzymes, SKF 525A, was administered 
alone and concomitantly with DBT for 4 days. The effects of such 
treatments on PHA and serum alanine transaminase are shown in Figure 
13. DBT-induced elevation of alanine transaminase is completely 
inhibited by SKF 525A. 
PHA is elevated in both the DBT and SKF 525A groups. However, 
PHA in the DBT/SKF 525A group is less than what would be expected 
if the effect of these drugs on this enzyme are additive. Indeed, 
the interactive effect is significant as determined by a multifactorial 
analysis of variance with the treatment variables DBT and SKF 525A. 
This interaction is not likely to be a result of threshold prolyl 
hydroxylase activation since higher levels (4-fold) have been 
observed in experimental liver injury after 4 days of treatment with 
dimethylnitrosamine (Ristelli et al., 1978). The prolyl hydroxylase 
values in DBT/SKF 525A-treated rats are not erroneously low due to 
altered liver protein content since there is no .change in the latter 
in any group. There is a positive correlation between PHA and serum 
alanine transaminase values in the control and DBT groups (r=+o.83). 
However, the correlation between these two parameters in the control 
and SKF 525A groups is negative (r=-0.81). This suggests that DBT-
induced PHA elevation is associated with parenchymal liver injury, 
and that of SKF 525A is independent of such injury and caused at 
least in part by a different mechanism. 
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Periportal inflammation and biliary injury, usually seen in 
DBT-treated rats after 4 days (Figure 6b), are absent in livers from 
rats that received SKF 525A in combination with DBT (Figure 16). 
Livers from this group of animals differ from control only in the 
presence of fatty infiltration. Livers from SKF 525A-treated rats 
are similar to those in the DBT/SKF 525A group; portal tracts show 
no evidence of fibrosis despite elevated PHA (Figure 14), but fatty 
infiltration is apparent throughout the parenchyma (Figure 15). 
SKF 525A has been shown to inhibit microsomal drug metabolizing 
enzymes (Niems et al., 1976), to prevent biliary excretion of xeno-
biotics through its effect on the metabolism of these compounds 
(Levine et al., 1970), and to prevent gastrointestinal absorption 
of certain drugs (McLean and Ma.rehang, 1970). Therefore, each of 
these effects must be considered as possible contributions to the 
pharmacologic interaction between DBT and SKF 525A. 
Microsomal oxidation of alkyltin compounds produces hydroxylated 
metabolites, some of which are highly unstable and rapidly destannyl-
ated (Kimmel et al., 1977) and some of which retain their biological 
activity (Aldridge et al., 1977). In the case of tributyltin meta-
bolites, which have been extensively studied, one has been shown 
to possess increased potency with respect to one of the parent 
compound's toxic effects, but the remaining four identified meta-
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bolites are either highly unstable or decreased in biologic activity 
(Aldridge et al., 1977). The product of DBT destannylation, ~ono­
butyltin, has been reported to be relatively devoid of toxic effects 
(Barnes and Magos, 1968). Thus, for microsomal metabolism to produce 
an overall increase in liver toxicity, the more stable metabolites of 
DBT would have to exhibit rather potent toxicity to compensate for 
the relative inertness of monoalkyltin. Since there is no evidence 
that metabolism of tri- or dialkyltin compounds substantially increases 
their toxicity, it is unlikely that the protective effect of SKF 525A 
is due to decreased production of toxic metabolites. 
Metabolism of DBT would be likely to increase the biliary ex-
cretion of this compound for two reasons. Firstly, metabolites would 
be likely to possess a more polar group thereby enhancing excretion 
(Kimmel et al., 1977; Levine, 1978). Secondly, microsomal metabolism 
would probably result in metabolites of increased molecular weight 
bringing the molecular weight of DBT (M.W. 304) above the approximate 
lower threshold value of between 200-300 (Levine, 1978). Thus, it 
seems likely that inhibition of metabolism by SKF 525A could decrease 
the biliary excretion of DBT and/or its metabolites. 
Finally, SKF 525A has been reported to impair gastrointestinal 
absorption of various drugs (M~Lean and Marchand, 1970). This effect 
is tempory, however. After one hour (one hour after drug administra-
tion and 1.5 hours after SKF 525A administration), blood levels of 
the drugs examined were actually significantly greater in SKF 525A-
treated rats compared to controls. With respect to DBT, 10 mg/kg/day, 
p.o • . administered to rats has been shown to increase PHA significantly 
by 4 days time (Yermakoff, 1978). Therefore, even if up to 50% of 
the administered dose was not absorbed, an elevation of liver PHA 
would still be anticipated in the presence of SKF 525A. It does 
not seem likely, therefore, that decreased gastrointestinal absorp-
tion of DBT by SKF 525A contributes substantially to the protective 
effects of the latter. 
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In summary, the pharmacologic interaction between DBT and SKF 525A 
may be due to multiple effects produced by SKF 525A including decreased 
production of toxic metabolites, decreased biliary excretion of DBT 
metabolites, and impaired gastrointestinal absorption of DBT. How-
ever, available information suggests that impaired biliary excretion 
via SKF 525A's inhibition of microsomal metabolism of DBT is likely 
to contribute subbtantially to the protective effect. Also, protection 
against DBT-induced liver injury by this inhibitor via its effects on 
microsomal metabolism may explain the age-related effects produced by 
this organotin compound. 
CONCLUSIONS 
(1) DBT administration from 0 to 4 days produces a gradual 
increase in prolyl hydroxylase activity (PHA) and in vitro collagen 
synthesis. These two parameters are significantly correlated (r=0.94). 
The biochemical changes are associated with the increasing appearance 
of inflammatory cells and ductular cell proliferation and injury 
during this same period. 
(2) At 4 days after DBT administration, serum alanine transamin-
ase is elevated approximately 4-fold. This is probably a sequela to 
the periportal inflammation since the hepatic injury observed at any 
time during the course of DBT treatment is associated wi~h inflamma-
tion. 
(3) Twelve days of DBT treatment (20 mg/kg, q.o.d.) results in 
increased PHA, increased protein synthesis directed toward collagen, 
and an increase in hydroxyproline content. These biochemical changes 
are associated with histologically demonstrable periportal fibrosis. 
(4) Serum alanine transaminase and alkaline phosphatase activities 
are not elevated after 12 days of DBT administration. The return to 
normal levels of serum alanine transaminase from the 4-fold increase 
at 4 days time is not unusual since this enzyme generally peaks 
early in the course of tissue injury. Normal alkaline phosphatase 
levels indicate that cholestasis is not a factor in DBT-induced liver 
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injury at this time. 
(5) Histopathology after 12 days of DBT treatment reveals 
extensive periportal inflammation and biliary injury in association 
with fibrosis. The contribution of inflammation to the development 
of fibrosis is supported by the modification of DBT-induced PHA ele-
vation by the nonsteroidal antiinflammatory drug, naproxen. 
(6) Rats 4 weeks of age are relatively resistant to the effects 
of DBT. In this 4-week-old group, PHA was 125% of control compared 
to 146% and 215% in the 9 and 14 week groups, respectively. Leuco-
cytosis and weight loss, usually associated with DBT-induced liver 
injury, are absent in these younger rats. 
(7) A thymocyte-dependent immunologic component of DBT's 
effects on the liver in the 9 and 14 week-old groups is suggested by 
the relative resistance of these 4-week-old rats with thymus atrophy 
to liver injury. Investigation of lymphocyte-mediated cytolysis, 
delayed-type hypersensitivity, and imnunofluorescence in DBT-treated 
rats failed to reveal such an immunologic component. 
(8) The relationship of differences in hepatic microsomal 
metabolism to the age-related effects of DBT was investigated using 
SKF 525A. There was a significant interaction with respect to the 
effects of DBT and SKF 525A on PHA. Administration of SKF 525A with 
DBT completely inhibited the increase in serum alanine transaminase 
seen with DBT alone after 4 days of treatment. Periportal inflammation 
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and biliary changes seen with DBT treatment alone were absent in these 
rats. Although the effects of SKF 525A may be due, in part, to the 
absence of DBT metabolites with greater biologic activity or impaired 
absorption of this organotin, they are more likely to involve de-
creased biliary excretion of the DBT and/or its metabolites. The 
interaction of SKF 525A with DBT suggests decreased biliary excretion 
via metabolism as a factor in the age-dependent effects produced by 
this organotin compound. 
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